A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

122

Enrollment

INDUSTRY

Sponsor class

Stopped The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.

Conditions

BRAF V600 Colorectal Cancer

Interventions

DRUG: Dabrafenib
DRUG: LTT462
DRUG: Trametinib
DRUG: LXH254
DRUG: TNO155
BIOLOGICAL: Spartalizumab
BIOLOGICAL: Tislelizumab

Sponsor

Novartis Pharmaceuticals